e-Drug3D

2114

MAVORIXAFOR

INN
MAVORIXAFOR

cas 558447-26-0

CLASS

BLOOD
CXC CHEMOKINE RECEPTOR 4 (CXCR4) ANTAGONIST
TREATMENT OF WHIM SYNDROME (WARTS, HYPOGAMMAGLOBULINEMIA, INFECTIONS AND MYELOKATHEXIS)

ROUTE (list)

ORAL

ATC code

L03AX24

PK parameters

Tmax 2.8 HOUR
VD 768 LITER
Cl 62 LITER / HOUR
PPB 93 PERCENT
t1/2 82 HOUR

Solubility

SLIGHTLY SOLUBLE IN PH 7.5 AQUEOUS BUFFER

Target

TARGET CXC CHEMOKINE RECEPTOR 4 (CXCR4)

Download SDF file

1,4-Butanediamine, N1-(1H-benzimidazol-2-ylmethyl)-N1-[(8S)-5,6,7,8-tetrahydro-8-quinolinyl]- (ACI)

Formula:
C21H27N5

Calculated chemical properties:

MW 349.48
NB_atoms 26
XLogP 3.58
PSA 61.99
NB_HD 3
NB_HA 5
fsp3 0.43
Lipinski(0=no;1=yes) 1

FDA
NDA 218709 (pdf not found) INN (MAVORIXAFOR) XOLREMDI (X4 PHARMS) APPROVAL= AP YEAR= 2024 NEWMOLECULARENTITY